Keila E. Torres, MD, PhD, MBA, FACS

Peer-Reviewed Articles

1. Valenzuela RF, Duran-Sierra E, Canjirathinkal M, Amini B, Torres KE, Benjamin RS, Ma J, Wang WL, Hwang KP, Stafford RJ, Wu C, Zarzour AM, Bishop AJ, Lo S, Madewell JE, Kumar R, Murphy Jr WA, Costelloe CM. Perfusion-weighted imaging with dynamic contrast enhancement (PWI/DCE) morphologic, qualitative, semiquantitative, and radiomics features predicting undifferentiated pleomorphic sarcoma (UPS) treatment response. Scientific Reports Nature 14(1):21681, 2024. PMID: 39289469.
2. Lyu HG, Witt RG, Rajkot N, Keung EZ, Torres KE, Hunt KK, Somaiah N, Lazar AJ, Roland CL, Scally CP. Patterns of care and outcomes of patients with small gastrointestinal stromal tumors at a high-volume sarcoma center. Ann Surg Oncol. e-Pub 2024. PMID: 39230849.
3. Bishop AJ, Mitra D, Farooqi AS, Swanson DM, Hempel CM, Derrick TW, Pearlnath CG, Wang WL, Ratan T, Somaiah N, Benjamin RS, Torres KE, Hunt KK, Scally CP, Keung EZ, Satcher R, Bird JE, Lin P, Moon BS, Lewis VO, Roland CL, Guadagnolo A. Moderately hypofractionated, preoperative radiotherapy in patients with soft tissue sarcomas (HYPORT-STS): updated local control, late-toxicities and patient-reported outcomes. Cancer. e-Pub 2024. PMID: 39192597.
4. Gingrich A, Wangsiricharoen S, Torres M, Ravi V, Ratan R, Keung EZ, Scally CP, Lazar A, Wang WL, Roland CL, Feig B, Hunt KK, Yu W, Torres KE. Clinical variables influencing outcomes in atypical intradermal smooth muscle neoplasms (formerly cutaneous leiomyosarcomas): Single institution study of 95 surgical patients. Ann Surg Oncol 31(12):7950-7956, 2024. PMID: 39150618.
5. Gingrich A, Wangsiricharoen S, Torres MB, Ravi V, Ratan R, Keung EZ, Scally CP, Lazar AJ, Wang WL, Roland CL, Hunt KK, Yu W, Torres KE. ASO Visual Abstract: Clinical Variables Influencing Outcomes in Patients with Atypical Intradermal Smooth Muscle Neoplasms (Formerly Cutaneous Leiomyosarcomas)-Single-Institution Study of 95 Surgical Patients. Ann Surg Oncol. e-Pub 2024. PMID: 39158635.
6. Valenzuela RF, Duran-Sierra E, Canjirathinkal M, Amini B, Torres KE, Benjamin RS, Ma J, Wang WL, Hwang KP, Stafford RJ, Wu C, Zarzour AM, Bishop AJ, Lo S, Madewell JE, Kumar R, Murphy Jr WA, Costelloe CM. Radiomics by quantitative diffusion weighted MRI for predicting response in patients with extremity soft-tissue undifferentiated pleomorphic sarcoma. J Radiol Oncol 8(2):064-071, 2024.
7. Traweek RS, Lyu HG, Witt RG, Snyder RA, Nassif EF, Krijgh DD, Smith JM, Tilney GS, Feng C, Chiang YJ, Torres KE, Roubaud MJ, Scally CP, Hunt KK, Keung EZ, Mericli AF, Roland CL. High community-level social vulnerability is associated with worse recurrence-free survival (RFS) after resection of extremity and truncal soft tissue sarcoma. Ann Surg Oncol 31(6):4138-4147, 2024. e-Pub 2024. PMID: 38396039.
8. Traweek RS, Lyu H, Witt RG, Snyder RA, Nassif EF, Krijgh DD, Smith JM, Tilney GS, Feng C, Chiang YJ, Torres KE, Roubaud MJ, Scally CP, Hunt KK, Keung EZ, Mericli AF, Roland CL. ASO Visual Abstract: High Community-Level Social Vulnerability is Associated with Worse Recurrence-Free Survival Following Resection of Extremity and Truncal Soft-Tissue Sarcoma. Ann Surg Oncol 31(6):4150-4151, 2024. PMID: 38546800.
9. Roland CL, Nassif Haddad EF, Keung EZ, Wang WL, Lazar AJ, Lin H, Chelvanambi M, Parra ER, Wani K, Guadagnolo BA, Bishop AJ, Burton EM, Hunt KK, Torres KE, Feig BW, Scally CP, Lewis VO, Bird JE, Ratan R, Araujo D, Zarzour MA, Patel S, Benjamin R, Conley AP, Livingston JA, Ravi V, Tawbi HA, Lin PP, Moon BS, Satcher RL, Mujtaba B, Witt RG, Traweek RS, Cope B, Lazcano R, Wu CC, Zhou X, Mohammad MM, Chu RA, Zhang J, Damania A, Sahasrabhojane P, Tate T, Callahan K, Nguyen S, Ingram D, Morey R, Crosby S, Mathew G, Duncan S, Lima CF, Blay JY, Fridman WH, Shaw K, Wistuba I, Futreal A, Ajami N, Wargo JA, Somaiah N. A randomized, non-comparative phase 2 study of neoadjuvant immune-checkpoint blockade in retroperitoneal dedifferentiated liposarcoma and extremity/truncal undifferentiated pleomorphic sarcoma. Nat Cancer 5(4):625-641, 2024. e-Pub 2024. PMID: 38351182.
10. Valenzuela RF, Duran-Sierra E, Canjirathinkal MA, Amini B, Ma J, Hwang KP, Stafford RJ, Torres KE, Zarzour MA, Livingston JA, Madewell JE, Murphy WA, Costelloe CM. Contrast-enhanced susceptibility weighted imaging (CE-SWI) for the characterization of musculoskeletal oncologic pathology: A pictorial essay on the initial five-year experience at a cancer institution. J Radiol Oncol(8):030-046, 2024.
11. Witt RG, Voss RK, Chiang YJ, Nguyen S, Scally CP, Lin PP, Torres KE, Moon BS, Satcher RL, Hunt KK, Bird JE, Feig BW, Lewis VO, Roland CL, Keung EZ. Practice pattern variability in the management of regional lymph node metastasis in extremity and trunk soft tissue sarcoma (ETSTS): A survey of the Society of Surgical Oncology (SSO) and Musculoskeletal Tumor Society (MSTS) Membership. Ann Surg Oncol 30(6):3668-3676, 2023. e-Pub 2023. PMID: 36723723.
12. Erstad DJ, Chiang YJ, Witt RG, Cope B, Nassif EF, Scally CP, Torres KE, Feig BW, Hunt KK, Bishop AJ, Guadagnolo BA, Roland CL, Keung EZ. Clinical impact of external beam radiotherapy for surgically resected primary retroperitoneal liposarcoma. Ann Surg Oncol 30(2):926-940, 2023. e-Pub 2022. PMID: 36115928.
13. Traweek RS, Martin AN, Rajkot NF, Guadagnolo BA, Bishop AJ, Lazar AJ, Keung EZ, Torres KE, Hunt KK, Feig BW, Roland CL, Scally CP. Re-excision after unplanned excision of soft tissue sarcoma is associated with high morbidity and limited pathologic identification of residual disease. Ann Surg Oncol 30(1):480-489, 2023. e-Pub 2022. PMID: 36085392.
14. Guadagnolo BA, Bassett RL, Mitra D, Farooqi A, Hempel C, Dorber C, Willis T, Wang WL, Ratan R, Somaiah N, Benjamin RS, Torres KE, Hunt KK, Scally CP, Keung EZ, Satcher RL, Bird JE, Lin PP, Moon BS, Lewis VO, Roland CL, Bishop AJ. Hypofractionated, 3-week, preoperative radiotherapy for patients with soft tissue sarcomas (HYPORT-STS): a single-centre, open-label, single-arm, phase 2 trial. Lancet Oncol 23(12):1547-1557, 2022. e-Pub 2022. PMID: 36343656.
15. Witt RG, Cope B, Erstad DJ, Chiang YJ, Nassif EF, Scally CP, Torres KE, Hunt KK, Feig BW, Roland CL, Keung EZ. Sentinel Lymph Node biopsy and formal lymphadenectomy for soft Tissue sarcoma – A single center experience of 86 consecutive cases. Ann Surg Oncol 29(11):7092-7100, 2022. e-Pub 2022. PMID: 35501583.
16. Rasmussen SV, Jin JX, Bickford LR, Woods AD, Sahm F, Crawford KA, Nagamori K, Goto H, Torres KE, Sidoni A, Rudzinski ER, Thway K, Jones RL, Ciulli A, Wright H, Lathara M, Srinivasa G, Kannan K, Huang PH, Grünewald TGP, Berlow NE, Keller C. Functional genomic analysis of epithelioid sarcoma reveals distinct proximal and distal subtype biology. Clin Transl Med 12(7):e961, 2022. PMID: 35839307.
17. Bhalla AD, Landers SM, Singh AK, Landry JP, Yeagley MG, Myerson GSB, Delgado-Baez CB, Dunnand S, Nguyen T, Ma X, Bolshakov S, Menegaz BA, Lamhamedi-Cherradi SE, Mao X, Song X, Lazar AJ, McCutcheon IE, Slopis JM, Ludwig JA, Lev DC, Rai K, Torres KE. Experimental models of undifferentiated pleomorphic sarcoma and malignant peripheral nerve sheath tumor. Lab Invest 102(6):658-666, 2022. e-Pub 2022. PMID: 35228656.
18. Nassif EF, Cope B, Traweek R, Witt RG, Erstad DJ, Scally CP, Thirasastr P, Zarzour MA, Ludwig J, Benjamin R, Bishop AJ, Guadagnolo BA, Ingram D, Wani K, Wang WL, Lazar AJ, Torres KE, Hunt KK, Feig BW, Roland CL, Somaiah N, Keung EZ. Real-World use of palbociclib monotherapy in retroperitoneal liposarcomas at a large volume sarcoma center. Int J Cancer 150(12):2012-2024, 2022. e-Pub 2022. PMID: 35128664.
19. DiPeri TP, Newhook TE, Day RW, Chiang YJ, Dewhurst WL, Arvide EM, Bruno ML, Scally CP, Roland CL, Katz MHG, Vauthey JN, Chang GJ, Badgwell BD, Perrier ND, Grubbs EG, Lee JE, Tzeng CD. PROMOTE Consortium: Torres KE, et al,. A prospective feasibility study evaluating the 5x-multiplier to standardize discharge prescriptions in cancer surgery patients. Surg Open Sci 25(9):51-57, 2022.
20. Voss RK, Callegaro D, Chiang YJ, Fiore M, Miceli R, Keung EZ, Feig BW, Torres KE, Scally CP, Hunt KK, Gronchi A, Roland CL. ASO Visual Abstract: Sarculator is a good model to predict survival in resected extremity and trunk sarcomas in US patients. Ann Surg Oncol. e-Pub 2022. PMID: 35254579.
21. Voss RK, Callegaro D, Chiang YJ, Fiore M, Miceli R, Keung EZ, Feig BW, Torres KE, Scally CP, Hunt KK, Gronchi A, Roland CL. Sarculator is a good model to predict survival in resected extremity and trunk sarcomas in US patients. Ann Surg Oncol. e-Pub 2022. PMID: 35224688.
22. Selber JC, Kameni L, Torres KE, Mericli A, Chu C, Schaverien M, Largo R, Butler C, Gaber O. Successful double DIEP syngeneic transplantation across monozygotic twins for total back reconstruction. Plast Reconstr Surg 148(5):1125-1133, 2021. PMID: 34705789.
23. Kochat V, Raman AT, Landers SM, Tang M, Schulz J, Terranova C, Landry JP, Bhalla AD, Beird HC, Wu CC, Jiang Y, Mao X, Lazcano R, Gite S, Ingram DR, Yi M, Zhang J, Keung EZ, Scally CP, Roland CL, Hunt KK, Feig BW, Futreal PA, Hwu P, Wang WL, Lazar AJ, Slopis JM, Wilson-Robles H, Wiener DJ, McCutcheon IE, Wustefeld-Janssens B, Rai K, Torres KE. Enhancer reprogramming in PRC2-deficient malignant peripheral nerve sheath tumors induces a targetable de-differentiated state. Acta Neuropathol 142(3):565-590, 2021. e-Pub 2021. PMID: 34283254.
24. Landry JP, Schertz KL, Chiang YJ, Bhalla AD, Yi M, Keung EZ, Scally CP, Feig BW, Hunt KK, Roland CL, Guadagnolo A, Bishop AJ, Lazar AJ, Slopis JM, McCutcheon IE, Torres KE. Comparison of cancer prevalence in patients with neurofibromatosis type 1 at an academic cancer center vs in the general population from 1985 to 2020. JAMA Netw Open 4(3):e210945, 2021. e-Pub 2021. PMID: 33734413.
25. Xu Y, Tsai CW, Chang WS, Xiong GY, Huang M, Torres KE, Bau DT, Gu J. Genetically predicted high circulating insulin-like growth factor-1 and insulin-like growth factor binding protein-3 increase the risks of soft tissue sarcoma. Am J Cancer Res 11(8):3980-3989, 2021. e-Pub 2021. PMID: 34522462.
26. Keung EZ, Rajkot N, Torres KE, Somaiah N, Hunt KK, Feig BW, Scally CP, Ikoma N, Roland CL. Evaluating the impact of surveillance follow-up intervals in patients following resection of primary well-differentiated liposarcoma of the retroperitoneum. Ann Surg Oncol 28(1):570-575, 2021. e-Pub 2020. PMID: 32409969.
27. Batth IS, Meng Q, Wang Q, Torres KE, Burks J, Wang J, Gorlick R, Li S. Rare osteosarcoma cell subpopulation protein array and profiling using imaging mass cytometry and bioinformatics analysis. BMC Cancer 20(1):715, 2020. e-Pub 2020. PMID: 32736533.
28. Bishop AJ, Landry JP, Roland CL, Ratan R, Feig BW, Moon BS, Zarzour MA, Wang WL, Lazar AJ, Lewis VO, Torres KE, Guadagnolo BA. Certain risk factors for patients with desmoid tumors warrant reconsideration of local therapy strategies. Cancer 126(14):3265-3273, 2020. e-Pub 2020. PMID: 32343846.
29. Keung EZ, Asare EA, Chiang YJ, Prakash LR, Rajkot N, Torres KE, Hunt KK, Feig BW, Cormier JN, Roland CL, Katz MHG, Lee JE, Tzeng CD. Postoperative pancreatic fistula after distal pancreatectomy for non-pancreas retroperitoneal tumor resection. Am J Surg 220(1):140-146, 2020. e-Pub 2019. PMID: 31843190.
30. Parkes A, Urquiola E, Bhosale P, Lin H, Watson K, Wang WL, Feig B, Torres KE, Roland CL, Conley AP, Zarzour M, Livingston JA, Ratan R, Ludwig J, Araujo DM, Ravi V, Benjamin RS, Patel S, Somaiah N. PET/CT Imaging as a diagnostic tool in distinguishing well-differentiated versus dedifferentiated liposarcoma. Sarcoma, 2020.
31. Xu Y, Xu J, Chancoco H, Huang M, Torres KE, Gu J. Long leukocyte telomere length is associated with increased risks of soft tissue sarcoma: A mendelian randomization study. Cancers (Basel) 12(3):594, 2020. e-Pub 2020. PMID: 32150919.
32. Asare EA, Davis CH, Chiang YJ, Sabir S, Rajkot NF, Phillips PR, Roland CL, Torres KE, Hunt KK, Feig BW. Management and outcomes of ruptured, perforated or fistulized tumors of mesenchymal origin. J Surg Oncol 121(3):474-479, 2020. e-Pub 2019. PMID: 31846095.
33. Landers SM, Bhalla AD, Ma X, Lusby K, Ingram D, Al Sannaa GA, Wang WL, Lazar AJ, Torres KE. AXL inhibition enhances MEK inhibitor sensitivity in malignant peripheral nerve sheath tumors. J Cancer Sci Clin Ther 4(4):511-525, 2020. e-Pub 2020.
34. Chrisinger JSA, Al-Zaid T, Keung EZ, Leung C, Lin HY, Roland CL, Torres KE, Benjamin RS, Ingram DR, Khan S, Somaiah N, Amini B, Feig BW, Lazar AJ, Wang WL. The degree of sclerosis is associated with prognosis in well-differentiated liposarcoma of the retroperitoneum. J Surg Oncol 120(3):382-388, 2019. e-Pub 2019.
35. Bishop AJ, Zarzour MA, Ratan R, Torres KE, Feig BW, Wang WL, Lazar AJ, Moon BS, Roland CL, Guadagnolo BA. Long-term outcomes for patients with desmoid fibromatosis treated with radiation therapy: an effective treatment but with poorer outcomes among young patients. Int J Radiat Oncol Biol Phys 103(5):1167-1174, 2019. e-Pub 2018. PMID: 30552963.
36. Fisher SB, Chiang YJ, Feig BW, Cormier JN, Hunt KK, Torres KE, Roland CL. An evaluation of the eighth edition of the American Joint Committee on Cancer (AJCC) staging system for retroperitoneal sarcomas using the National Cancer Data Base (NCDB): Does size matter?. Am J Clin Oncol 42(2):160-165, 2019. PMID: 30394881.
37. Fonseca AL, Roland CL, Cormier JN, Torres KE, Hunt KH, Bishop AJ, Guadagnolo A, Feig BW. Radiation and its impact on local recurrence in extremity and trunk well-differentiated liposarcomas. Am Surg 85(1):52-58, 2019. PMID: 30760345.
38. Keung EZ, Chiang YJ, Cormier JN, Torres KE, Hunt KK, Feig BW, Roland CL. Treatment at low-volume hospitals is associated with reduced short-term and long-term outcomes for patients with retroperitoneal sarcoma. Cancer 124(23):4495-4503, 2018. e-Pub 2018. PMID: 30317543.
39. Young ED, Ingram D, Metcalf-Doetsch W, Khan D, Al Sannaa GA, Le Loarer F, Lazar AJ, Slopis J, Torres KE, Lev D, Pollock RE, McCutcheon IE. Clinicopathologic variables of sporadic schwannomas of peripheral nerve in 291 patients and expression of biologically relevant markers. J Neurosurg 129(3):805-814, 2018. e-Pub 2017. PMID: 28885122.
40. Keung EZ, Lazar AJ, Torres KE, Wang WL, Cormier JN, Ashleigh Guadagnolo B, Bishop AJ, Lin H, Hunt KK, Bird J, Lewis VO, Patel SR, Wargo JA, Somaiah N, Roland CL. Phase II study of neoadjuvant checkpoint blockade in patients with surgically resectable undifferentiated pleomorphic sarcoma and dedifferentiated liposarcoma. BMC Cancer 18(1):913, 2018. e-Pub 2018. PMID: 30249211.
41. Shasby G, Young ED, Ingram D, Metcalf-Doetsch W, Khan D, Al Sannaa G, Le Loarer F, Lazar AJF, Slopis J, Torres KE, Lev D, Pollock RE, McCutcheon IE. Erratum: Clinicopathological variables of sporadic schwannomas of peripheral nerve in 291 patients and expression of biologically relevant markers. J Neurosurg 129(3):838, 2018. PMID: 29125411.
42. Ikoma N, Roland CL, Torres KE, Chiang YJ, Wang WL, Somaiah N, Mann GN, Hunt KK, Cormier JN, Feig BW. Salvage surgery for recurrent retroperitoneal well-differentiated liposarcoma: Early reoperation may not provide benefit. Ann Surg Oncol 25(8):2193-2200, 2018. e-Pub 2018.
43. Bishop AJ, Zagars GK, Torres KE, Bird JE, Feig BW, Guadagnolo BA. Malignant peripheral nerve sheath tumors: A single institution's experience using combined surgery and radiation therapy. Am J Clin Oncol 41(5):465-470, 2018.
44. Fisher SB, Chiang YJ, Feig BW, Cormier JN, Hunt KK, Torres KE, Roland CL. Comparative performance of the 7th and 8th editions of the American Joint Committee on Cancer staging systems for soft tissue sarcoma of the trunk and extremities. Ann Surg Oncol 25(5):1126-1132, 2018. e-Pub 2018.
45. Ikoma N, Roland CL, Torres KE, Chiang YJ, Wang WL, Somaiah N, Mann GN, Hunt KK, Cormier JN, Feig BW. Concomitant organ resection does not improve outcomes in primary retroperitoneal well-differentiated liposarcoma: A rertrospective cohort study at a major sarcoma center. J Surg Oncol 117(6):1188-1194, 2018. e-Pub 2017.
46. Ikoma N, Roland CL, Cormier JN, Chiang YJ, Torres KE, Hunt KK, You YN, Feig BW. Nongastrointestinal stromal tumor spindle cell sarcomas of the colon or rectum. Am Surg 84(4):570-575, 2018. PMID: 29712608.
47. Roland CL, Bednarski BK, Watson K, Torres KE, Cormier JN, Wang WL, Lazar AJ, Somaiah N, Hunt KK, Feig BW. Identification of preoperative factors associated with outcomes following surgical management of intra-abdominal recurrent or metastatic GIST following neoadjuvant tyrosine kinase inhibitor therapy. J Surg Oncol 117(5):879-885. e-Pub 2018.
48. Li H, Meng QH, Noh H, Somaiah N, Torres KE, Xia X, Batth IS, Joseph CP, Liu M, Wang R, Li S. Cell-surface vimentin-positive macrophage-like circulating tumor cells as a novel biomarker of metastatic gastrointestinal stromal tumors. Oncolmmunology 7(5):e1420450. e-Pub 2018.
49. Cancer Genome Atlas Research Network. [Adbani R, Byers LA, Chin L, Lazar A, Lu Y, Mills GB, Roszik J, Torres KE, Wang J, Weinstein JN]. Electronic address: elizabeth.demicco@sinaihealthsystem.ca., Cancer Genome Atlas Research Network. Comprehensive and integrated genomic characterization of adult soft tissue sarcomas. Cell 171(4):950-965.e28, 2017. PMID: 29100075.
50. Keung EZ, Chiang YJ, Voss RK, Cormier JN, Torres KE, Hunt KK, Feig BW, Roland CL. Defining the incidence and clinical significance of lymph node metastasis in soft tissue sarcoma. Eur J Surg Oncol 44(1):170-177. e-Pub 2017.
51. Voss RK, Chiang YJ, Torres KE, Guadagnolo BA, Mann GN, Feig BW, Cormier JN, Roland CL. Adherence to national comprehensive cancer network guidelines is associated with improved survival for patients with stage 2A and stages 2B and 3 extremity and superficial trunk soft tissue sarcoma. Ann Surg Oncol 24(11):3271-3278, 2017. e-Pub 2017. PMID: 28741122.
52. May CD, Landers SM, Bolshakov S, Ma X, Ingram DR, Kivlin CM, Watson KL, Al Sannaa GA, Bhalla AD, Wang WL, Lazar AJ, Torres KE. Co-targeting PI3K, mTOR, and IGF1R with small molecule inhibitors for treating undifferentiated pleomorphic sarcoma. Cancer Biol Ther 8(10):816-826, 2017. e-Pub 2017. PMID: 29099264.
53. Keung EZ, Tsai JW, Ali AM, Cormier JN, Bishop AJ, Guadagnolo BA, Torres KE, Somaiah N, Hunt KK, Wargo JA, Lazar AJ, Wang WL, Roland CL. Analysis of the immune infiltrate in undifferentiated pleomorphic sarcoma of the extremity and trunk in response to radiotherapy: Rationale for combination neoadjuvant immune checkpoint inhibition and radiotherapy. Oncoimmunology 7(2):e1385689, 2017.
54. Ikoma N, Torres KE, Lin HY, Ravi V, Roland CL, Mann GN, Hunt KK, Cormier JN, Feig BW. Recurrence patterns of retroperitoneal leiomyosarcoma and impact of salvage surgery. J Surg Oncol 116(3):313-319, 2017. e-Pub 2017.
55. Li H, Meng QH, Noh H, Batth IS, Somaiah N, Torres KE, Xia X, Hsu FJ, Wang R and Li S. Detection of circulating tumor cells from cryopreserved human sarcoma peripheral blood mononuclear cells. Cancer Letter:216-223, 2017. e-Pub 2017. PMID: 28652021.
56. Dodd RD, Lee CL, Overton T, Huang W, Eward WC, Luo L, Ma Y, Ingram DR, Torres KE, Cardona D, Lazar AJ, Kirsch DG. NF1+/- Hematopoietic cells accelerate malignant peripheral nerve sheath tumor development without altering chemotherapy response. Cancer Res 77(16):4486-4497, 2017. e-Pub 2017.
57. Panse G, Leung CH, Ingram DR, Wani K, Torres KE, Lin H, Lazar AJ, Wang WL. The role of phosphorylated signal transducer and activator of transcription 3 (pSTAT3) in peripheral nerve sheath tumors. Histopathology 70(6):946-953, 2017. e-Pub 2017. PMID: 27992966.
58. Watson KL, Al Sannaa GA, Kivlin CM, Ingram DR, Landers SM, Roland CL, Cormier JN, Hunt KK, Feig BW, Ashleigh Guadagnolo B, Bishop AJ, Wang WL, Slopis JM, McCutcheon IE, Lazar AJ, Torres KE. Patterns of recurrence and survival in sporadic, neurofibromatosis Type 1-associated, and radiation-associated malignant peripheral nerve sheath tumors. J Neurosurg 126(1):319-329, 2017. e-Pub 2016.
59. Al Sannaa GA, Watson KL, Wang WL, Fuller GN, McCutcheon I, Torres KE, Lazar AJ.. Sarcoma Brain Metastases: 28 years of experience at a single institution. Ann Surg Oncol 23(Suppl 5):962-967, 2016. e-Pub 2016. PMID: 27646022.
60. de Graaff MA, Yu JS, Beird HC, Ingram DR, Nguyen T, Juehui Liu J, Bolshakov S, Szuhai K, Åman P, Torres KE, Lev D, Nielsen TO, Bovée JV, Lazar AJ, Somaiah N. Establishment and characterization of a new human myxoid liposarcoma cell line (DL-221) with the FUS-DDIT3 translocation. Lab Invest 96(8):885-94, 2016. e-Pub 2016.
61. Roland CL, May CD, Watson KL, Al Sannaa GA, Dineen SP, Feig R, Landers S, Ingram DR, Wang WL, Guadagnolo BA, Feig B, Hunt KK, Cormier JN, Lazar AJ, Torres KE. Analysis of clinical and molecular factors impacting oncologic outcomes in undifferentiated pleomorphic sarcoma. Ann Surg Oncol 23(7):2220-8, 2016. e-Pub 2016. PMID: 26847678.
62. Cleven AH, Al Sannaa GA, Briaire-de Bruijn I, Ingram DR, van de Rijn M, Rubin BP, de Vries MW, Watson KL, Torres KE, Wang WL, van Duinen SG, Hogendoorn PC, Lazar AJ, Bovée JV. Loss of H3K27 tri-methylation is a diagnostic marker for malignant peripheral nerve sheath tumors and an indicator for an inferior survival. Mod Pathol 29(6):582-90, 2016. e-Pub 2016.
63. Roland CL, Boland GM, Demicco EG, Lusby K, Ingram D, May CD, Kivlin CM, Watson K, Al Sannaa GA, Wang WL, Ravi V, Pollock RE, Lev D, Cormier JN, Hunt KK, Feig BW, Lazar AJ, Torres KE. Clinical observations and molecular variables of primary vascular leiomyosarcoma. JAMA Surg 151(4):347-54, 2016. PMID: 26629783.
64. Kivlin CM, Watson KL, Al Sannaa GA, Belousov R, Ingram DR, Huang KL, May CD, Bolshakov S, Landers SM, Kalam AA, Slopis JM, McCutcheon IE, Pollock RE, Lev D, Lazar AJ, Torres KE. Poly (ADP) ribose polymerase inhibition: A potential treatment of malignant peripheral nerve sheath tumor. Cancer Biol Ther 17(2):129-38, 2016. e-Pub 2015. PMID: 26650448.
65. Bishop AJ, Zagars GK, Torres KE, Hunt KK, Cormier JN, Feig BW, Guadagnolo BA. Combined modality management of retroperitoneal sarcomas: a single institution series of 121 patients. Int J Radiat Oncol Biol Phys 93(1):158-65, 2015. e-Pub 2015. PMID: 26130233.
66. Brudvik KW, Patel SH, Roland CL, Conrad C, Torres KE, Hunt KK, Cormier JN, Feig BW, Aloia TA, Vauthey JN. Survival after resection of gastrointestinal stromal tumor and sarcoma liver metastases in 146 patients. J Gastrointest Surg 19(8):1476-83, 2015. e-Pub 2015. PMID: 26001368.
67. Keung E, Akdemir K, Al Sannaa GA, Garnett J, Lev D, Torres KE, Lazar A, Rai K, Chin L.. Increased H3K9me3 drives dedifferentiated phenotype via KLF6 repression in liposarcoma. J Clin Investigation 125(8):2965-78, 2015.
68. Demicco EG, Harms PW, Patel RM, Smith SC, Ingram D, Torres KE, Carskadon SL, Camelo-Piragua S, McHugh JB, Siddiqui J, Palanisamy N, Lucas DR, Lazar AJ, Wang WL. Extensive survey of STAT6 expression in a large series of mesenchymal tumors. Am J Clin Pathol 143(5):672-82, 2015.
69. Ikoma N, Torres KE, Somaiah N, Hunt KK, Cormier JN, Tseng W, Lev D, Pollock R, Wang WL, Feig B. Accuracy of preoperative percutaneous biopsy for the diagnosis of retroperitoneal liposarcoma subtypes. Ann Surg Oncol 22(4):1068-72, 2015. e-Pub 2014.
70. Demicco EG, Boland GM, Brewer Savannah KJ, Lusby K, Young ED, Ingram D, Watson KL, Bailey M, Guo X, Hornick JL, van de Rijn M, Wang WL, Torres KE, Lev D, Lazar AJ. Progressive loss of myogenic differentiation in leiomyosarcoma has prognostic value. Histopathology 66(5):627-38, 2015. e-Pub 2015. PMID: 24889065.
71. Dineen SP, Roland CL, Feig R, May C, Zhou S, Demicco E, Al Sannaa GA, Ingram D, Wang WL, Ravi V, Guadagnolo A, Lev D, Pollock RE, Hunt K, Cormier J, Lazar A, Feig B, Torres KE. Radiation-Associated undifferentiated pleomorphic sarcoma is associated with worse clinical outcomes than sporadic lesions. Ann Surg Oncol. e-Pub 2015.
72. Zhang P, Yang X, Ma X, Ingram DR, Lazar AJ, Torres KE, Pollock RE. Antitumor effects of pharmacological EZH2 inhibition on malignant peripheral nerve sheath tumor through the miR-30a and KPNB1 pathway. Mol Cancer 14(1):55, 2015. PMID: 25890085.
73. Chinyengetere F, Sekula DJ, Lu Y, Giustini AJ, Sanglikar A, Kawakami M, Ma T, Burkett SS, Eisenberg BL, Wells WA, Hoopes PJ, Demicco EG, Lazar AJ, Torres KE, Memoli V, Freemantle SJ, Dmitrovsky E. Mice null for the deubiquitinase USP18 spontaneously develop leiomyosarcomas. BMC Cancer 15:886, 2015. e-Pub 2015. PMID: 26555296.
74. May CD, Garnett J, Ma X, Landers SM, Ingram DR, Demicco EG, Al Sannaa GA, Vu T, Han L, Zhang Y, Kivlin CM, Bolshakov S, Kalam AA, Liu J, Zhou F, Broccoli D, Wang WL, Lazar AJ, Pollock RE, Lev D, Torres KE. AXL is a potential therapeutic target in dedifferentiated and pleomorphic liposarcomas. BMC Cancer 15:901, 2015. e-Pub 2015. PMID: 26573603.
75. Peng X, Li W, Johnson WD, Torres KE, McCormick DL. Overexpression of lipocalins and pro-inflammatory chemokines and altered methylation of PTGS2 and APC2 in oral squamous cell carcinomas induced in rats by 4-nitroquinoline-1-oxide. PLoS One 1(e0116285), 2015.
76. Bednarski BK, Araujo DM, Yi M, Torres KE, Lazar A, Trent JC, Cormier JN, Pisters PW, Lev DC, Pollock RE, Feig BW, Hunt KK. Analysis of prognostic factors impacting oncologic outcomes after neoadjuvant tyrosine kinase inhibitor therapy for gastrointestinal stromal tumors. Ann Surg Oncol 21(8):2499-505, 2014. e-Pub 2014. PMID: 24639192.
77. Behjati S, Tarpey PS, Sheldon H, Martincorena I, Van Loo P, Gundem G, Wedge DC, Ramakrishna M, Cooke SL, Pillay N, Vollan HK, Papaemmanuil E, Koss H, Bunney TD, Hardy C, Joseph OR, Martin S, Mudie L, Butler A, Teague JW, Patil M, Steers G, Cao Y, Gumbs C, Ingram D, Lazar AJ, Little L, Mahadeshwar H, Protopopov A, Al Sannaa GA, Seth S, Song X, Tang J, Zhang J, Ravi V, Torres KE, Khatri B, Halai D, Roxanis I, Baumhoer D, Tirabosco R, Amary MF, Boshoff C, McDermott U, Katan M, Stratton MR, Futreal PA, Flanagan AM, Harris A, Campbell PJ. Recurrent PTPRB and PLCG1 mutations in angiosarcoma. Nat Genet 46(4):376-9, 2014. e-Pub 2014. PMID: 24633157.
78. Satelli A, Mitra A, Cutrera JJ, Devarie M, Xia X, Ingram DR, Dibra D, Somaiah N, Torres KE, Ravi V, Ludwig JA, Kleinerman ES, Li S. Universal marker and detection tool for human sarcoma circulating tumor cells. Cancer Res 74(6):1645-50, 2014. e-Pub 2014. PMID: 24448245.
79. Banda M, Speyer CL, Semma SN, Osuala KO, Kounalakis N, Torres KE, Barnard NJ, Kim HJ, Sloane BF, Miller FR, Goydos JS, Gorski DH. Metabotropic glutamate receptor-1 contributes to progression in triple negative breast cancer. PLoS One 9(1):e81126, 2014. e-Pub 2014. PMID: 24404125.
80. Hoffman A, Ghadimi MP, Demicco EG, Creighton CJ, Torres KE, Colombo C, Peng T, Lusby K, Ingram D, Hornick JL, Wang WL, Ravi V, Lazar AJ, Lev D, Pollock RE. Localized and metastatic myxoid/round cell liposarcoma: clinical and molecular observations. Cancer 119(10):1868-77, 2013. e-Pub 2013. PMID: 23401071.
81. Torres KE, Ravi V, Kin K, Yi M, Guadagnolo BA, May CD, Arun BK, Hunt KK, Lam R, Lahat G, Hoffman A, Cormier JN, Feig BW, Lazar AJ, Lev D, Pollock RE. Long-term outcomes in patients with radiation-associated angiosarcomas of the breast following surgery and radiotherapy for breast cancer. Ann Surg Oncol 20(4):1267-74, 2013. e-Pub 2012. PMID: 23224828.
82. Ghadimi MP, Lopez G, Torres KE, Belousov R, Young ED, Liu J, Brewer KJ, Hoffman A, Lusby K, Lazar AJ, Pollock RE, Lev D. Targeting the PI3K/mTOR Axis, alone and in combination with autophagy blockade, for the treatment of malignant peripheral nerve sheath tumors. Mol Cancer Ther 11(8):1758-69, 2012. e-Pub 2012. PMID: 22848094.
83. Torres KE, Lazar A, Pollock R, Lev A. Angiosarcoma: A frequently recurrent and highly metastatic malignancy. Eur J Clin Med Oncol 4(2):73-81, 2012.
84. Demicco EG, Torres KE, Ghadimi MP, Colombo C, Bolshakov S, Hoffman A, Peng T, Bovée JV, Wang WL, Lev D, Lazar AJ. Involvement of the PI3K/Akt pathway in myxoid/round cell liposarcoma. Mod Pathol 25(2):212-21, 2012. e-Pub 2011. PMID: 22020193.
85. Ghadimi MP, Liu P, Peng T, Bolshakov S, Young ED, Torres KE, Colombo C, Hoffman A, Broccoli D, Hornick JL, Lazar AJ, Pisters P, Pollock RE, Lev D. Pleomorphic liposarcoma: Clinical observations and molecular variables. Cancer 117(23):5359-69, 2011. e-Pub 2011. PMID: 21598240.
86. Lahat G, Zhang P, Zhu QS, Torres KE, Ghadimi M, Smith KD, Wang WL, Lazar AJ, Lev D. The expression of c-Met pathway components in unclassified pleomorphic sarcoma/malignant fibrous histiocytoma (UPS/MFH): a tissue microarray study. Histopathology 59(3):556-561, 2011. PMID: 22034893.
87. Torres KE, Liu J, Young E, Huang KL, Ghadimi M, Lusby K, Lazar AJ, Lev D. Expression of 'drugable' tyrosine kinase receptors in malignant peripheral nerve sheath tumour: potential molecular therapeutic targets for a chemoresistant cancer. Histopathology 59(1):156-9, 2011. PMID: 21771036.
88. Torres KE, Zhu QS, Bill K, Lopez G, Ghadimi MP, Xie X, Young ED, Liu J, Nguyen T, Bolshakov S, Belousov R, Wang S, Lahat G, Liu J, Hernandez B, Lazar AJ, Lev D. Activated MET is a molecular prognosticator and potential therapeutic target for malignant peripheral nerve sheath tumors. Clin Cancer Res 17(12):3943-55, 2011. e-Pub 2011. PMID: 21540237.
89. Lopez G, Torres KE, Lev D. Autophagy blockade enhances HDAC inhibitors' pro-apoptotic effects: Potential implications for the treatment of a therapeutic-resistant malignancy. Autophagy 7(4):440-1. e-Pub 2011.
90. Lopez G, Torres KE, Liu J, Hernandez B, Young E, Belousov R, Bolshakov S, Lazar AJ, Slopis JM, McCutcheon IE, McConkey D, Lev D. Autophagic survival in resistance to histone deacetylase inhibitors: novel strategies to treat malignant peripheral nerve sheath tumors. Cancer Res 71(1):185-96, 2011. e-Pub 2010. PMID: 21084276.
91. Ylipää A, Hunt KK, Yang J, Lazar AJ, Torres KE, Lev DC, Nykter M, Pollock RE, Trent J, Zhang W. Integrative genomic characterization and a genomic staging system for gastrointestinal stromal tumors. Cancer 117(2):380-9, 2011. e-Pub 2010. PMID: 20818650.
92. Wang S, Ren W, Liu J, Lahat G, Torres KE, Lopez G, Lazar AJ, Hayes-Jordan A, Liu K, Bankson J, Hazle JD, Lev D. TRAIL and doxorubicin combination induces proapoptotic and antiangiogenic effects in soft tissue sarcoma in vivo. Clin Cancer Res 16(9):2591-604, 2010. e-Pub 2010. PMID: 20406839.
93. Lahat G, Zhu QS, Huang KL, Wang S, Bolshakov S, Liu J, Torres KE, Langley RR, Lazar AJ, Hung MC, Lev D. Vimentin is a novel anti-cancer therapeutic target; insights from in vitro and in vivo mice xenograft studies. PLoS One 5(4):e10105, 2010. e-Pub 2010. PMID: 20419128.
94. Torres KE, Burd RS. Recent nationwide trends in the utilization of pectus repairs in children. J Surg Res 137(2):328-329, 2007.
95. Gorski D, Schell SR, Kounalakis N, Torres KE, Barnard NJ, Goydos JS, Chen S. Elevated metabotropic glutamate receptor expression: a novel finding in invasive breast cancer. J Surg Res 130(2):164, 2006.
96. Gold JP, Torres KE, Maldarelli W, Zhuravlev I, Condit D, Wasnick J. Improving outcomes in coronary surgery: the impact of echo-directed aortic cannulation and perioperative hemodynamic management in 500 patients. Ann Thorac Surg 78(5):1579-85, 2004. PMID: 15511435.
97. Gold JP, Wasnick J, Maldarelli W, Zhuraavlev I, Torres KE, Condit D. Selective use of off-pump coronary bypass surgery reduces mortality and neurologic morbidity associated with high-risk coronary bypass surgery: a 400-case comparative experience. Heart Surg Forum 7(6):e562-8, 2004. PMID: 15769687.
98. Martello LA, Verdier-Pinard P, Shen HJ, He L, Torres KE, Orr GA, Horwitz SB. Elevated levels of microtubule destabilizing factors in a Taxol-resistant/dependent A549 cell line with an alpha-tubulin mutation. Cancer Res 63(6):1207-13, 2003. PMID: 12649178.
99. Torres KE, Horwitz SB. Mechanisms of taxol-induced cell death are concentration dependent. Cancer Res 58(16):3620-6, 1998. PMID: 9721870.
100. Báez A, Torres KE, Tan EM, Pommier Y, Casiano CA. Expression of proliferation-associated nuclear autoantigens, p330d/CENP-F and PCNA, in differentiation and in drug-induced growth inhibition using two-parameter flow cytometry. Cell Prolif 29(4):183-96, 1996. PMID: 8695747.
101. Goldwasser F, Bae I, Valenti M, Torres KE, Pommier Y. Topoisomerase I-related parameters and camptothecin activity in the colon carcinoma cell lines from the National Cancer Institute anticancer screen. Cancer Res 55(10):2116-21, 1995. PMID: 7743511.
102. Valenzuela RF, Duran-Sierra E, Canjirathinkal M, Torres KE, Wang WL, Hwang KP, Stafford J.. The novel use of contrast-enhanced susceptibility imaging (CE-SWI), the value of morphologic T2* "complete-ring" sign, and CE-SWI-DERIVED first and high-order radiomic features predicting treatment response in extremity soft-tissue non-myxoid undifferentiated pleomorphic sarcoma (UPS). JCO Precision Oncology.
103. Shih TC, Wang HC, Torres KE, Xia R, Malogolowkin M, Hsu SW, Chen CH. Therapeutic efficacy of galectin-1 inhibitor in treating malignant peripheral nerve sheath tumor. Cancer Research.

Invited Articles

1. Roland CL, Wang WL, Lazar AJ, Torres KE. Myxofibrosarcoma. Surg Oncol Clin N Am 25(4):775-88, 2016. PMID: 27591498.
2. Zhang P, Torres KE, Liu X, Liu CG, Pollock RE. An Overview of Chromatin-Regulating Proteins in Cells. Curr Protein Pept Sci 17(5):401-10, 2016. PMID: 26796306.

Manuals, Teaching Aids, Other Teaching Publications

1. Torres KE, Zhu Q, Lev D. Targeting the P13K/AKT pathway in UPS/MFH. Electronic Sarcoma Update Newsletter (ESUN): http://sarcomahelp.org/research_center/UPS-MFH_study.html, 2011.
2. Torres KE, Pollock RE. Alveolar Soft Part Sarcoma. Electronic Sarcoma Update Newsletter (ESUN): http://sarcomahelp.org/learning_center/asps.html, 2010.
3. Moufflet A, Moore J, Panarelli A, Madrid D, Schimmrich K, Pevzner L, Torres KE, Angel M, Zahtz E, Sorbellini M, Koppolu S, Cuevas J, Frogel D, Grinspan Z, Spector J, Hirsh D, Vouyiouklis M. AECOM Dissector Online. http://storm.aecom.yu.edu/virtualDissector, 2001.

Abstracts

1. Chatterjee B, Kochat V, Satpati S, Landers SM, Bhalla AD, Torres KE, Rai K. Epigenome Dysregulation in NF1-Associated Malignant Peripheral Nerve Sheath Tumors. 2024 Cancer Neuroscience Symposium, 2024.
2. Denu RA, Segura RL, Farooqi AS, Ingram D, Wani KM, Cai Y, Torres KE, Keung EZ, Roland CL, Somaiah N, Ying H, Huse JT, Rai K, Conley AP, Patel S, Wang WL, Lazar AJ, Haddad EFN. Impact of ATRX loss on survival and immune microenvironment in multiple sarcomasubtypes. Accepted for Poster presentation at the 2024 American Society of Clinical Oncology in Chicago, Illinois, 2024.
3. Munnangi P, King BL, Chiang YS, Conley AP, Araujo DM, Livingston A, Ludwig JA, Nakazawa M, Haddad EFN, Ravi V, Ratan R, Zarzour MA, Patel S, Torres KE, Somaiah N. Systemic therapy in NF-1 associated malignant peripheral nerve sheath tumors (MPNST). Accepted for Poster presentation at the 2024 American Society of Clinical Oncology in Chicago, Illinois, 2024.
4. Gingrich A, Landers S, Bhalla A, Keung EZ, Scally CP, Roland CL, Hunt KK, Guadagnolo A, Slopis J, McCutcheon I, Livingston JA, Farooqi A, Torres KE. Role of Bromodomain Extra Terminal Inhibitor (BETi) in Combination with Radiotherapy for the Treatment of Malignant Peripheral Nerve Sheath Tumor in Neurofibromatosis Type 1 Patients. Accepted for Poster presentation at the 2024 AACR Annual Meeting in San Diego, California, 2024.
5. Gingrich A#, Montgomery AE#, Munnangi P, Landers S, Wangsiricharoen S, Bhalla A, Lin PP, Lewis VO, Moon BS, Satcher R, Frink SJ, Shreyaskumar S, Lyu H, Lillemoe H, Scally C, Keung E, Roland CL, Hunt KK, Slopis J, McCutcheon I, Lazar A, Wang WL, Bird JE, Yu W, Eberlin LS*, Torres KE*. #Co-First authors , *Co-Senior authors. P64: MasSpec Pen Technology for Molecular Identification of MPNST Surgical Margin Assessment. Accepted for Oral presentation at the 2024 Society of Surgical Oncology in Atlanta, GA, 2024.
6. Montgomery AE, Munnangi P, Gingrich A, Landers S, Wangsiricharoen S, Bhalla A, Lin PP, Lewis VO, Moon BS, Shreyaskumar S, Lyu H, Lillemoe H, Scally C, Keung E, Roland CL, Hunt KK, McCutcheon I, Bird JE, Yu W, Eberlin LS*, Torres KE*. *Co-Senior authors. P59: Evaluation of the MasSpec Pen Technology for Molecular Identification of Sarcomas and Surgical Margin Assessment. Accepted for Oral presentation at the 2024 Society of Surgical Oncology in Atlanta, GA, 2024.
7. Munnangi P#, Montgomery AE#, Gingrich A, Landers S, Wangsiricharoen S, Bhalla A, Lin PP, Lewis VO, Moon BS, Shreyaskumar S, Scally C, Keung EZ, Roland CL, Hunt KK, McCutcheon I, Bird JE, Yu W, Eberlin LS*, Torres KE*. #Co-First authors,*Co-Senior authors. E420: Use of the MasSpec Pen Technology for accurate determination of surgical margins of myxofibrosarcomas (MFS). Accepted for Poster presentation at the 2024 Society of Surgical Oncology Conference in Atlanta, GA, 2024.
8. Landers SM, Bhalla AD, Rodriguez-Aguayo C, Keung E, Scally C, Roland C, Hunt K, Lyu H, Lillemoe HA, Guadagnolo A, Lazar A, McCutcheon I, Livingston JA, Farooqi A, Torres KE. Treatment of Malignant Peripheral Nerve Sheath Tumor with Bromodomain Extra Terminal Inhibitor (Beti) in Combination with Radiotherapy. Accepted for Poster presentation at the 2024 CTOS Annual Meeting in San Diego, CA, 2024.
9. Oliveras A*, Ramirez A*, Nguyen G*, Bhalla AD, Landers SM, Rodriguez-Aguayo C, Torres KE. *Contributed Equally. Inhi-BET-ing Bromodomain Containing Protein 4 (BRD4) to Improve Radiation Therapy Response in Malignant Peripheral Nerve Sheath Tumors. Accepted for Poster Presentation at the 2024 U54 Partnership Summer Research for Excellence in Cancer Research in San Juan, Puerto Rico, 2024.
10. Ramirez A, Oliveras A, Nguyen G, Bhalla AD, Landers SM, Rodriguez-Aguayo C, Torres KE. Sensitizing Malignant Peripheral Nerve Sheath Tumors to Radiation Therapy by Inhibiting Bromodomain Proteins. Accepted for Poster Presentation at the 2024 CATALYST Training Program Symposium in Houston, Texas, 2024.
11. Traweek RS, Lazcano R, Cope BM, Bishop AJ, Guadagnolo BA, Ingram DR, Wani K, Lazar AJ, Wang WL, Scally CP, Keung EZ, Torres KE, Hunt KK, Nassif EF, Roland CL. Major Pathologic Response (MPR) Following Neoadjuvant Radiation Therapy (RT) +/- immune-checkpoint Blockade (ICB) Is Associated with Improved Survival in Undifferentiated Pleomorphic Sarcoma (UPS). Accepted for oral presentation at the 105th Annual Meeting of the American Radium Society in Lahaina, Maui, 2023.
12. Gingrich A, Torres M, Bonsu NY, Ravi V, Ratan R, Keung EZ, Scally CP, Lazar A, MD, Wang WL, Roland CL, Feig B, Hunt KK, Yu W, Torres KE. Clinical Variables Influencing Outcomes in Atypical Intradermal Smooth Muscle Neoplasms (Formerly Cutaneous Leiomyosarcomas): Single Institution Study of 95 Surgical Patients. Accepted for oral presentation at the 105th Annual Meeting of the American Radium Society in Lahaina, Maui, 2023.
13. Gingrich A, Wangsiricharoen S, Torres M, Ravi V, Ratan R, Keung EZ, Scally CP, Lazar A, Wang WL, Roland CL, Feig B, Hunt KK, Yu W, Torres KE. Clinical Variables Influencing Outcomes in Atypical Intradermal Smooth Muscle Neoplasms (Formerly Cutaneous Leiomyosarcomas): Single Institution Study of 95 Surgical Patients. Accepted for poster presentation at the SSO 2023 – International Conference on Surgical Cancer Care in Boston, MA, 2023.
14. Montgomery AE, Bird JE, Fletcher D, Landers S, Wangsiricharoen S, Wei-Lien W, Wendong Y, Eberlin LS, Torres KE. Application of the MasSpec Pen Technology for Molecular Identification of Human Sarcomas and Surgical Margin Evaluation. Accepted for oral presentation at the 71st ASMS Conference on Mass Spectrometry and Allied Topics in Houston, TX, 2023.
15. Tomczak K, Patel SS, Peterson C, Landers S, Bhalla AD, Landry JP, Callahan C, Lazar AJ, McCutcheon I, Slopis JM, Livingston JA, Guadagnolo BA, Zhang D, Wong J, Keung EZ, Scally C, Roland C, Hunt K, Gu J, Scheet P, Wang L, Rai K, Torres KE. Plasma DNA Methylation-Based Biomarkers for MPNST Detection in Patients with Neurofibromatosis Type 1 (NF1). Accepted for Poster presentation at the 2023 Connective Tissue Oncology Society Annual Meeting in Dublin, Ireland, 2023.
16. Gingrich AA, Beird H, Chu R, Traweek R, Cope B, Keung EZ, Scally C, Hunt K, Torres KE, MD, Roland C, Futreal PA, Co-Author: Bishop AJ, Guadagnolo BA, Mitra D, Farooqi A, Araujo DM, Zarzour M, Livingston JA, Conley AP, Patel SS, Ravi V, Somaiah N, Lazar AJ, Ratan R, Nassif E. Leiomyosarcoma Intratumoral Macrophage Infiltrates are Associated with Distinct Clinical and Genomic Presentations. Accepted for Poster presentation at the 2023 Connective Tissue Oncology Society Annual Meeting in Dublin, Ireland, 2023.
17. Lillemoe HA, Hunt K, Subramaniam A, Keung EZ, Roland C, Torres KE, Lyu H, Scally C, Mitra D, Farooqi A, Bishop AJ, Guadagnolo BA, Ravi V. Primary Breast Angiosarcoma: Clinical and Pathological Features and Impact on Outcomes. Accepted for Poster presentation at the 2023 Connective Tissue Oncology Society Annual Meeting in Dublin, Ireland, 2023.
18. Farooqi A, Yoder A, Mitra D, Scally C, Moon B, Lin P, Goepfert R, Torres KE, Bird J, Hunt K, Lewis V, Roland C, Guadagnolo BA. How Should Radiation Therapy be Incorporated Into The Multidisciplinary Management of Soft Tissue Sarcomas Following an Unplanned Excision?. Accepted for Oral presentation at the 2023 Connective Tissue Oncology Society Annual Meeting in Dublin, Ireland, 2023.
19. Bishop AJ, Mitra D, Farooqi A, Hempel C, Bagchi C, Willis T, Pearlnath C, Wang WL, Ratan R, Somaiah N, Benjamin R, Torres KE, Hunt K, Scally C, Satcher R, Bird J, Lin P, Moon B, Lewis V, Roland C, Guadagnolo BA. Long-Term Disease Outcomes, Late Toxicity, and Function Following Hypofractionated Preoperative Radiation Therapy for Patients with Soft Tissue Sarcomas: A Hyport-STS Update. Accepted for Oral presentation at the 2023 Connective Tissue Oncology Society Annual Meeting in Dublin, Ireland, 2023.
20. Torres KE, Montgomery A, Bird J, Landers S, Fletcher D, Wangsiricharoen S, Lin P, Lewis V, Moon B, Satcher R, Frink S, Shreyaskumar Patel S, Scally C, Keung E, Roland C, Hunt K, McCutcheon I, Wang WL, Yu W, Eberlin L. Evaluation of the Masspec Pen Technology for Molecular Identification of Bone and Soft Tissue Sarcomas and Surgical Margin Assessment. Accepted for Oral presentation at the 2023 Connective Tissue Oncology Society Annual Meeting in Dublin, Ireland, 2023.
21. Lillemoe HA, Hunt K, Subramaniam A, Keung EZ, Roland C, Torres KE, Lyu H, Scally C, Mitra D, Farooqi A, Bishop AJ, Guadagnolo BA, Ravi V. Leiomyosarcoma intratumoral macrophage infiltrates are associated with distinct clinical and genomic presentations. Accepted for Poster presentation at the 2023 Connective Tissue Oncology Society Annual Meeting in Dublin, Ireland, 2023.
22. Montgomery A, Bird J, Landers S, Fletcher D, Wangsiricharoen S, Lin, P, Lewis V, Moon B, Satcher R, Frink S, Patel SS, Scally C, Keung EZ, Roland C, Hunt K, McCutcheon I, Wei-Lien Wang, MD, Yu W, Eberlin L, Torres KE. Evaluation of the Masspec Pen Technology for Molecular Identification of Bone and Soft Tissue Sarcomas and Surgical Margin Assessment. Accepted for Oral presentation at the 2023 Connective Tissue Oncology Society Annual Meeting in Dublin, Ireland, 2023.
23. Witt RG, Voss RK, Chiang YJ, Nguyen Sa, Scally CP, Lin PP, Torres KE, Moon BS, Satcher RL, Hunt KK, Bird JE, Feig BW, Lewis VO, Roland CL, Keung EZ. Practice Patterns in the Management of Regional Lymph Node Metastasis in Soft Tissue Sarcoma: A Survey of The Society of Surgical Oncology and Musculoskeletal Tumor Society Membership. Accepted for oral presentation at the 2022 Connective Tissue Oncology Society Annual Meeting in Vancouver, BC, Canada, 2022.
24. Traweek RS, Witt RG, Nassif EF, Ajami NJ, Mishra AK, Damania AV, Chelvanambi M, Wang WL, Lazar AJ, Keung EZ, Torres KE, Scally CP, Zhang X, Daniel-MacDougall CR, Wargo JA, Somaiah N, Roland CL. Dietary fiber intake is associated with increased tertiary lymphoid structures in dedifferentiated liposarcoma following immune checkpoint blockade. Accepted for oral presentation at the Society for Immunotherapy of Cancer in Boston, MA, 2022.
25. Nassif E, Liu B, Wang WL, Lazar A, Ingram DR, Wani KM, Duncan S, Tate TJ, Mathew G, Crosby SD, Shaw KR, Zelazowska MA, Feig BW, Torres KE, Hunt KK, Guadagnolo A, Bishop AJ, Futreal A, Wargo J, Somaiah N, McBride K, Roland CL, Keung E. B-Cell Receptor (BCR) Repertoire is a Dynamic Biomarker of Survival in Sarcoma Patients Treated with Neoadjuvant Immune Checkpoint Blockade (ICB). Accepted for oral presentation at the Society for Immunotherapy of Cancer in Boston, MA, 2022.
26. Kochat V, Chatterjee B, Satpati S, Callahan SC, McLaughlin ME, Dede M, Chou JH, Landers SM, Lazcano Segura RN, Singh AK, Lazar A, Li W, Hart T, Rai K, Torres KE. Dependency of PRC2-mutant MPNSTs on RNA exosome machinery. Oral Presentation at the TRANSCEND Symposium, 2022.
27. Landry J, Kochat V, Satpati S, Bhalla AD, Landers SM, Parker LA, Miller TM, Ingram D Keung E, Scally C, Roland CL, Hunt KK, Slopis J, McCutcheon I, Boudreau B, Wilson-Robles H, Lazcano Segura RN, Lazar AJ, Wiener D, Davis B, Rai K, Wustefeld-Janssens B, Torres KE. Comparative clinical genomic and epigenomic study of human and canine malignant peripheral nerve sheath tumors (MPNST). Poster Presentation at the TRANSCEND Symposium in Houston, TX, 2022.
28. Pemberton J, Bhalla A, Landers S, Kochat V, Torres KE. Effects of ZIC1 Enhancer Silencing in Malignant Peripheral Nerve Sheath Tumors. Poster presentation and Winner of the Scientific Poster Competition. Partnership for Careers in Cancer Science and Medicine (PCCSM) Symposium in Houston, TX, 2022.
29. Nassif EF, Wu CC, Akdemir K, Witt RG, Traweek R, Cope B, Thirasastr P, Tate T, Mathew G, Crosby S, Chu R, Mohammad M, Shaw K, Davis Ingram D, Wani K, Lazar AJ, Wang WL, Duncan S, B. Guadagnolo BA, Bishop AJ, Lewis V, Bird JE, Torres KE, Hunt KK, Feig BW, Scally CP, Ratan R, Patel SP, Benjamin R, Satcher R, McBride K, Fridman WH, Wistuba I, Futreal A, Wargo JA, Somaiah N, Roland CL, Keung EZ. Antigen presentation and processing pathway is associated with early relapse after neoadjuvant immune checkpoint blockade (ICB) in dedifferentiated liposarcomas (DDLPS). Accepted for oral presentation at the American Association Cancer for Cancer Research Conference on Sarcomas in Montreal, QC, Canada, 2022.
30. Lyu HG, Lillemoe HA, Chiang YJ, Keung EZ, Nguyen ST, Peterson SK, Torres KE, Hunt K, Feig BW, Bishop AJ, Guadagnolo BA, Somaiah N, Roland CL, Scally C. Health-Related Quality of Life in patients with resectable undifferentiated pleomorphic sarcoma treated with neoadjuvant checkpoint blockade in a single institution randomized phase II clinical trial. Accepted for oral presentation at the 2022 ASCO Annual Meeting in Chicago, IL, 2022.
31. Keung EZ, Nassif EF, Lin HY, Lazar AJ, Torres KE, Wang WL, Guadagnolo BA, Bishop AJ, Hunt K, Feig BW, Bird JE, Lewis VO, Ratan R, Patel S, Zelazowska M, Liu B, McBride K, Wargo JA, Roland CL, Somaiah N. Randomized phase II study of neoadjuvant checkpoint blockade for surgically resectable undifferentiated pleomorphic sarcoma (UPS) and dedifferentiated liposarcoma (DDLPS): survival results after 2 years of follow-up and intratumoral B-Cell Receptor (BCR) correlates. Accepted for oral presentation #365268 at the 2022 ASCO Annual Meeting in Chicago, IL, 2022.
32. Landry JP, Kochat V, Landers SM, Bhalla AD, Lazcano R, Parker L, Miller T, Ingram DR, Wiener D, Davis B, Boudreau B, Wang WL, Keung EZ, Scally CP, Roland CL, Hunt KK, Feig BW, Slopis JM, Wilson-Robles H, Lazar A, Rai K, Wustefeld-Janssens B, Torres KE. Comparative Review of Human and Canine Peripheral Nerve Sheath Tumors. Accepted for oral presentation at the 2021 Connective Tissue Oncology Society Virtual Meeting, 2021.
33. Mitra D, Farooqi A, Hempel C, Dorber C, Mathai R, Wang WL, Ratan R, Torres KE, Somaiah N, Hunt KK, Scally CP, Keung EZ, Satcher R, Bird JE, Lin P, Moon B, Lewis V, Roland CL, Bishop AJ, Guadagnolo BA. Prospective Single-Arm Controlled Trial of 3-Week-Course Hypofractionated Preoperative Radiotherapy for Soft Tissue Sarcoma of the Extremity or Trunk. Accepted for oral presentation at the 2021 Connective Tissue Oncology Society Virtual Meeting, 2021.
34. Erstad DJ, Chiang YJ, Witt RG, Scally CP, Torres KE, Feig BW, Hunt KK, Bishop AJ, Guadagnolo BA, Roland CL, Keung EZ. Clinical Impact of External Beam Radiotherapy for Surgically Resected Primary Retroperitoneal Liposarcoma. Accepted for poster presentation at the 2021 Western Surgical Society Annual Meeting in Indian Wells, CA, 2021.
35. Nassif EF, Roland CL, Thirasastr P, Scally CP, Zarzour A, Valenzuela R, Torres KE, Hunt KK, Feig BW, Wang WL, Lazar AJ, Somaiah N, Keung EZ. Surgical Outcomes of Patients with Well-Differentiated and Dedifferentiated Retroperitoneal Liposarcomas Treated with Palbociclib. Accepted poster presentation at the 2021 Connective Tissue Oncology Society Virtual Meeting, 2021.
36. Witt RG, Chiang YJ, Erstad DJ, Scally CP, Torres KE, Hunt KK, Feig BW, Roland CL, Keung EZ. Sentinel Lymph Node Biopsy and Formal Lymphadenectomy for Soft Tissue Sarcoma – A Single Center Experience of 86 Consecutive Cases. Accepted for oral presentation at the 2021 Connective Tissue Oncology Society Virtual Meeting, 2021.
37. Stark AP, Bathala T, Hunt KK, Torres KE, Keung EZ, Scally CP, Feig BW, Roland CL. Preoperative Localization of Non-Palpable Primary and Recurrent Soft Tissue Sarcoma Using Magseed ®. Accepted for poster presentation at the SSO 2020 – International Conference on Surgical Cancer Care in San Diego, CA, 2020.
38. Tomczak KJ, Peterson CB, Callahan SC, Landers SM, Terranova CJ, Serrao GSB, Bhalla AD, Landry JP, Mulder ZA, Yeagley MG, Bolshakov S, Ayush R, Gardenhire EL, Ingram D, Lazar A, Wang WL, McCutcheon IE, Slopis J, Rai K, Torres KE. DNA Methylation-Based Biomarkers for MPNST Detection in Patients with Neurofibromatosis Type 1. Poster presentation at the AACR Annual Meeting in San Diego, CA, 2020.
39. Stark AP, Rajkot N, Ikoma N, Chiang YJ, Wang WL, Roland CL, Torres KE, Zarzour MA, Ravi V, Hunt KK, Feig BW. Evaluation of Response to Preoperative Therapy and Outcome in Primary Retroperitoneal Leiomyosarcoma. Accepted for poster presentation at the SSO 2020 – International Conference on Surgical Cancer Care in San Diego, CA, 2020.
40. Landry JP, Yeagley M, Ingram DR, Chiang YJ, Keung EZ, Scally CP, Feig BW, Hunt KK, Roland CL, Cormier JN, Torres KE. Clinical Variables Influencing Outcome for Alveolar Soft Part Sarcoma: Results from 152 Patients at a Single Institution. Accepted for poster presentation at the SSO 2020 – International Conference on Surgical Cancer Care in Boston, MA, 2020.
41. Keung EZ, Rajkot N, Cormier JN, Torres KE, Somaiah N, Hunt KK, Feig BW, Ikoma N, Roland CL. The Impact of Surveillance Interval Following Resection of Primary Well Differentiated Liposarcoma of the Retroperitoneum. Accepted for poster presentation at the South Texas Chapter of the American College of Surgeons Annual Meeting in Houston, TX, 2020.
42. Landry JP, Schertz K, Chiang YJ, Roland CL, Keung EZ, Scally CP, Wang WL, Lazar AJ, Feig BW, Hunt KK, Slopis JM, McCutcheon IE, Torres KE. Cancer Risk in Patients with Neurofibromatosis Type 1. Poster presentation at the SSO 2019 – International Conference on Surgical Cancer Care in San Diego, CA, 2019.
43. Davis CH,* Asare EA, Sabir S, Roland CL, Torres KE, Hunt KK, Cormier JN, Feig BW. Management and Outcomes of Patients with Fistulized Mesenchymal Tumors. Poster presentation at the SSO 2019 – International Conference on Surgical Cancer Care, San Diego, CA, 2019.
44. Keung EZ,* Asare EA, Chiang YJ, Prakash LR, Rajkot N, Roland CL, Torres KE, Cormier JN, Hunt KK, Feig BW, Lee JE, Katz MHG, Tzeng CD. Postoperative Pancreatic Fistula and Morbidity After Distal Pancreatectomy for Non-Pancreas Retroperitoneal Tumor Resection. Poster presentation at the SSO 2019 – International Conference on Surgical Cancer Care in San Diego, CA, 2019.
45. Keung EZ, Rajkot N, Cormier JN, Torres KE, Hunt KK, Feig BW, Ikoma N, Roland CL. The Impact of Surveillance Interval Following Resection of Primary Well Differentiated Liposarcoma of The Retroperitoneum. Poster Presentation at CTOS Annual Meeting in Tokyo, Japan, 2019.
46. Roland CL, Keung EZ, Lazar AJ, Wang WL, Cormier JN, Guadagnolo BA, Bishop AJ, Mujtaba B, Lin HY, Torres KE, Hunt KK, Feig BW, Bird JE, Lewis VO, Patel SR, Wargo JA, Somaiah N. Phase II Study of Neoadjuvant Checkpoint Blockade in Patients with Surgically Resected Undifferentiated Pleomorphic Sarcoma and Dedifferentiated Liposarcoma-Preliminary Safety Data. Poster Presentation at CTOS Annual Meeting in Tokyo, Japan, 2019.
47. Ikoma N, Wang W-L, Roland C, Torres KE, Vinod R, Hunt K, Cormier J, Feig B. Evaluation of Treatment Response to Preoperative Therapy in Retroperitoneal Leiomyosarcoma. Presented at CTOS Annual Meeting in Rome, Italy, 2018.
48. Sandler G, Chiang Y-J, Cormier J, Hunt K, Lazar AJ, Lynch P, Roland C, Torres KE, You YN, Feig B. A Clinical Comparison of Familial (APC Mutated) vs Sporadic (CTNB1 Mutated) Desmoid Tumors. Presented at CTOS Annual Meeting in Rome, Italy, 2018.
49. Bishop AJ, Zarzour MA, Ratan R, Torres KE, Feig B, Wang W-L, Lazar AJ, Moon B, Roland C, Guadagnolo BA. Young Patients with Desmoid Fibromatosis Have High Rates of Local Recurrence: Is It Time to Rethink Treatment Strategies in This Subset?. Presented at CTOS Annual Meeting in Rome, Italy, 2018.
50. Kochat V, Raman A, Landers S, Terranova C, Wu C-C, Mao X, Ingram D, Mulder Z, Yeagley M, Beird H, Bhalla A, Slopis J, McCutcheon I, Zhang J, Futreal P, Wang W-L, Lazar AJ, Rai K, Torres KE. Chromatin State Transitions Associated with PRC2 Functional Loss Drive a De-Differentiated Phenotype in Malignant Peripheral Nerve Sheath Tumors. Presented at CTOS Annual Meeting in Rome, Italy, 2018.
51. Kochat V, Raman A, Landers SM, Teranova C, Wu CC, Mao X, Ingram D, Mulder ZA, Yeagley MG, Bierd H, Bhalla A, McCutcheon I, Slopis J, Zhang J, Futreal A, Wang WL, Lazar A, Rai K, Torres KE. Oncogenic Role of EZH2 in the Pathogenesis of Malignant Peripheral Nerve Sheath Tumors with Functionally Inactive Polycomb Repressor Complex 2. Accepted for poster presentation at the 2018 Keystone Symposia Conference on Cancer Epigenetics: New Mechanisms, New Therapies in Breckenridge, CO, 2018.
52. Holder AM, Chiang K, Torres KE, Cormier J, Ravi V, Mann GN, Hunt KK, Feig BW, Roland C. Identifying Patients Most Likely to Benefit from Salvage Surgery for Recurrent or Metastatic Uterine Leiomyosarcoma. Accepted for Poster Presentation at the 2017 SSO Meeting in Seattle, WA, 2017.
53. Grotz TE, Schertz K, Yeagley M, Guadagnolo AB, Somaiah N, Hunt KK, Cormier JN, Feig B, Wang WL, Lazar A, Torres KE, Roland CL. Evaluation of Neoadjuvant Therapy in the Treatment of Myxoid Liposarcoma, Connective Tissue Oncology Society. Presented at the 2017 Connective Tissue Oncology Society Meeting in Maui, HI, 2017.
54. Ikoma N, Roland CL, Chiang YJ, Torres KE, Hunt KK, Somaiah N, Cormier JN, Feig BW. Timing and Extent of Surgical Resection for Recurrent Retroperitoneal Well-Differentiated Liposarcoma. Accepted for Poster Presentation at the 2017 SSO Meeting in Seattle, WA, 2017.
55. Voss R, Cormier J, Chiang YJ, Torres KE, Feig B, Hunt KK, Mann G, Roland CL. Adherence to Stage-Specific Treatment Guidelines for Stages IIA & IIB/III Extremity and Trunk Soft Tissue Sarcoma is Associated with Superior Survival. Accepted for Poster Presentation at the 2016 SSO Meeting in Boston, MA, 2016.
56. Roland CL, Watson K, Chiang YJ, Liang Y, DeRosa N, Mann G, Cormier JN, Hunt KK, Feig BW, Wang WL, Lazar A, Torres KE. Oncologic Outcomes in Patients with Extremity Myxofibrosarcoma (MFS) and Undifferentiated Pleomorphic Sarcoma: A Matched Case-Control Study. Accepted for poster presentation at the 2016 CTOS Annual Meeting in Lisbon, Portugal, 2016.
57. Ikoma N, Roland C, Torres KE, Mann G, Hunt KK, Cormier J, Feig BW. Does Extended Surgical Resection Improve Outcomes in Primary Retroperitoneal Well-Differentiated Liposarcoma?. Accepted for poster presentation at the 2016 CTOS Annual Meeting in Lisbon, Portugal, 2016.
58. Grotz TE, Torres KE, Guadagnolo A, Wang W, Somaiah N, Mann GN, Cormier J, Hunt KK, Feig B.. Inguinal Liposarcoma: Is Local Resection Alone Adequate?. Accepted for Poster Presentation at the 2016 Accepted for Poster Presentation at the 2016 SSO Meeting in Boston, MA, 2016.
59. Roland C, Bednarski B, Watson K, Torres KE, Cormier J, Mann GN, Wang W, Lazar A, Somaiah, N, Hunt KK, Feig B.. Surgical Management of Patients with Recurrent or Intra-Abdominal Metastatic GIST Following Neoadjuvant Tyrosine Kinase Inhibitor Therapy: Who is Benefiting?. Accepted for Poster Presentation at the 2016 SSO Meeting in Boston, MA, 2016.
60. Ikoma N, Watson KL, Roland CL, Hunt KK, Cormier J, Mann GN, Torres KE, Feig B.. Surgical Resection of Recurrent Leiomyosarcoma of the Retroperitoneum May be Beneficial. Accepted for Poster Presentation at the 2016 SSO Meeting in Boston, MA, 2016.
61. Roland C, Dineen S, Watson K, Al Sannaa GA, Feig R, May C, Ingram D, Wang WL, Lazar A, Ravi V, Hunt KK, Cormier J, Feig B, Torres KE. Variations in Protein Expression are Associated with Survival Outcomes in Patients with Undifferentiated Pleomorphic Sarcomas. Accepted for Oral Presentation at the 2015 Society of Surgical Oncology Annual Cancer Symposium in Houston, TX, 2015.
62. Somaiah N, Beird H, Shaw K, Want WL, Conley A, Ravi V, Torres KE, Ingram D, Roland C, Subbiah V, Feig B, Lazar A, Benjamin R, Patel S, Hwu P, Futreal A, Meric-Bernstam F, Hong D. Targeted next generation sequencing in well-differentiated/dedifferentiated liposarcoma (WD/DD LPS): multiple gene amplifications but few recurrent mutations. Accepted for Poster Presentation at the 2015 Annual ASCO Meeting in Chicago, IL, 2015.
63. Kivlin CM, Huang KL, Bolshakov S, May CD, Landers SM, Kalam AA, McCutcheon IE, Slopis JM, Lazar AJ, Torres KE. Unraveling the sensitivity of Malignant Peripheral Nerve Sheath Tumor (MPNST) to Poly (ADP) Ribose Polymerase inhibition. Accepted for Poster Presentation at the 2015 Children’s Tumor Foundation Neurofibromatosis Conference in Monterey, CA, 2015.
64. Somaiah N, Bhosale P, Lin H, Feig B, Torres KE, Watson K, Roland CL, Conley A, Patel S, Benjamin R. PET/CT Imaging Might Be Superior to Percutaneous Biopsy in Identifying Dedifferentiation in Patients with Well-Differentiated (WDLS)/Dedifferentiated Liposarcoma (DDLS). Accepted for Poster Presentation at the 2015 CTOS Annual Meeting in Salt Lake City, 2015.
65. Cleven A, Ghada A, Briaire de Bruijn I, Ingram D, van de Rijn M, de Vries M, Watson K, Torres KE, van Duinen S, Hogendoom P, Lazar AJ, Bovee J. Loss of H3k27 tri-methylation is a diagnostic marker for malignant peripheral nerve sheath tumors and an indicator for an inferior survival. Accepted for Poster Presentation at the 2015 CTOS Annual Meeting in Salt Lake City, UT, 2015.
66. de Rosa N, Watson K, Orr WS, Wang WL, Lazar A, Roland C, Cormier J, Hunt KK, Feig B, Torres KE. Determinants of Recurrence and Survival in Myxofibrosarcoma (MFS). Accepted for Poster Presentation at the 2015 Society of Surgical Oncology Annual Cancer Symposium in Houston, TX, 2015.
67. Orr WS, Watson K, Feig R, Ikoma N, de Rosa N, Giacco G, Ravi V, Benjamin R, Madewell J, Cormier J, Hunt KK, Roland C, Feig B, Torres KE. Is F-18 fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET/CT) of value in soft tissue sarcoma management?. Accepted for Poster Presentation at the 2015 Society of Surgical Oncology Annual Cancer Symposium in Houston, TX, 2015.
68. Ikoma N, Landers S, Watson K, Al Sannaa GA, Ingram D, Wang WL, Lazar A, Somaiah N, Roland C, Cormier J, Hunt KK, Feig B, Torres KE. Clinicopathologic Comparison of Retroperitoneal Undifferentiated Pleomorphic Sarcoma and Dedifferentiated Liposarcoma. Accepted for Poster Presentation at the 2015 Society of Surgical Oncology Annual Cancer Symposium in Houston, TX, 2015.
69. Ikoma N, Tseng W, Torres KE, Hunt KK, Cormier JN, Somaiah N, Feig B. Accuracy of Percutaneous Biopsy for Retroperitoneal Liposarcoma. Accepted for Poster Presentation at the 2014 Society of Surgical Oncology Cancer Symposium in Phoenix, Arizona, 2014.
70. Ikoma N, Chiang Y, Cormier JN, Torres KE, Hunt KK, You Y, Feig B. Spindle Cell Tumors of the Colon and Rectum. Accepted for Poster Presentation at the 2014 Society of Surgical Oncology Cancer Symposium in Phoenix, Arizona, 2014.
71. Dineen S, May C, Feig R, Hunt KK, Cormier JN, Feig B, Sannaa A, Ingram D, Wang W, Lazar A, Ravi V, Torres KE. Radiation-associated Unclassified Pleomorphic Sarcoma is Associated with Worse Clinical Outcomes compared to Sporadic Lesions. Accepted for Oral Presentation at the 2014 Society of Surgical Oncology Cancer Symposium in Phoenix, Arizona, 2014.
72. Keung E, Rai K, Akdemir K, Al Sannaa G, Garnett J, Torres KE, Lazar A, Chin L. Identification of Kruppel-Like Factor 6 (KLF6) as a Differentially Expressed Transcription Factor in Well Differentiated and Dedifferentiated Liposarcoma (WDLPS, DDLPS) through Unbiased Epigenetic Approaches. Accepted for Podium Presentation at the 21st Annual NESS Surgical Resident and Fellow Research Presentation Day at UMass Medical Center in Worcester, 2014.
73. Ravi V, Ramesh N, Patnana M, Conley A, Somaiah N, Lazar A, Aroujo D, Torres KE, Ali S, Miller V, Benjamin R, Hwu P, Hunt KK, Patel S, Futreal A. Targeted Sequencing of Leiomyosarcomas in the Clinic: Potential for Target Identification. Accepted for Poster Presentation at the Connective Tissue Oncology Society Meeting in Berlin, Germany, 2014.
74. Roland C, Watson K, Al Sannaa G, Feig R, May C, Ingram D, Wang WL, Lazar A, Feig B, Hunt KK, Cormier J, Torres KE. Expression and Significance of Microorna-1, -133A, -182 and -183 in Patients with Undifferentiated Pleomorphic Sarcoma (UPS). Accepted for Poster Presentation at the Connective Tissue Oncology Society Meeting in Berlin, Germany, 2014.
75. Keung E, Lazar A, Akdemir K, Al Sannaa G, Garnett J, Torres KE, Rai K, Chin L. Functional Validation of Kruppel-Like Factor 6 as a Differentially Expressed and Epigenetically Regulated Transcription Factor with Novel Tumor Suppressor Role in Liposarcoma. Accepted for Poster Presentation at the Connective Tissue Oncology Society Meeting in Berlin, Germany, 2014.
76. Livingston J, Bugano D, Madewell J, Wang WL, Conley A, Ravi V, Araujo D, Tseng W, Feig B, Torres KE, Benjamin R, Patel S, Somaiah N. Assessing Chemotherapy Benefit in Well-Differentiated/De-Differentiated Liposarcoma. Accepted for Poster Presentation at the Connective Tissue Oncology Society Meeting in Berlin, Germany, 2014.
77. Ravi V, Ramesh N, Conley A, Somaiah N, Torres KE, Benjamin R, Wang WL, Hwu P, Patel S, Rohren E. Predicting Survival Using FDG-PET Responses in Patients with Unclassified Sarcoma. Accepted for Poster Presentation at the Connective Tissue Oncology Society Meeting in Berlin, Germany, 2014.
78. Keung EZ, Rai K, Kadir AC, Al Sannaa G, Garnett J, Torres KE, Lazar AJ, Chin L. Identification of Kruppel-Like Factor 6)KLF6) as a differently expressed transcription factor and tumor suppressor in well differentiated and dedifferentiated liposarcoma (WDLPS, DDLPS) through unbiased epigenetic approaches. Presentation at the ACS American College of Surgeons Clinical Congress in San Francisco, CA, 2014.
79. Al Sannaa G, Torres KE, Ingram D, Wang WL, Lazar AJ. Emerging immunohistochemical markers for malignant peripheral nerve sheath tumor (MPNST). Accepted for Poster Presentation at the CAP 2014 The Pathologists Meeting in Chicago, IL, 2014.
80. Ravi V, Ramesh N, Patnana M, Conley A, Somaiah N, Zarzour M, Ingram D, Little L, Cao Y, Gumbs C, Mahadeshwar H, Protopopov A, Sannaa G, Seth S, Song X, Tang J, Lazar A, Zhang J, Araujo D, Torres KE, Ali S, Miller V, Stephens P, Benjamin R, Hwu R, Patel S, Futreal A. Whole Exome and Targeted Sequencing of Angiosarcomas: Target identification and treatment implications. Accepted for Poster Presentation at the 2014 ASCO Annual Meeting in Chicago, IL, 2014.
81. Boland G, Demicco EG, Lusby K, Ingram D, Palmer JD, Lazar AJ, Cormier J, Hunt K, Pollock RE, Lev D, Torres KE. Vascular Leiomyosarcomas: clinical observations and molecular variables. Accepted for Oral Presentation at the Society of Surgical Oncology's 66th Annual Cancer Symposium in National Harbor, Maryland, 2013.
82. Kivlin CM, Ma XY, Ingram D, Al Sannaa GA, Feng Y, May C, Bolshakov S, McCutcheon I, Slopis J, Lev D, Lazar AJ, Torres KE. BMN 673, A novel portent PARP inhibitor for the treatment of Malignant Peripheral Nerve Sheath Tumor (MPNST). Accepted for Poster Presentation at the CTOS 2013 Annual Meeting in New York, NY, 2013.
83. Kivlin CM, Ma XY, Zhu QS, Belousov R, Ingram D, Al Sannaa GA, May C, Garnett J, Bolshakov S, McCutcheon I, Slopis J, Pollock RE, Lev D, Lazar AJ, Torres KE. Downregulation of ERCC6 a potential mechanism for the effect of PARP inhibition in Malignant Peripheral Nerve Sheath Tumor (MPNST). Accepted for Poster Presentation at the CTOS 2013 Annual Meeting in New York, NY, 2013.
84. May CD, Ma X, Zhou F, Feig R, Ingram D, Al Sannaa GA, Kivlin C, Garnett J, Bolshakov S, Lazar AJ, and Torres KE. Combination of IGF1R Inhibition with PI3K/mTOR Blockade for the Treatment of Undifferentiated Pleomorphic Sarcoma/Malignant Fibrous Histiocytoma. Accepted for Poster Presentation at the CTOS 2013 Annual Meeting in New York, NY, 2013.
85. Ma X, Kivlin CM, May C, Uzunparmak B, Han L, Zhou G, Ingram D, Al Sannaa GA, Garnett J, Bolshakov S, McCutcheon I, Slopis J, Lev D, Lazar AJ, Torres KE. Inhibition of AXL enhances the sensitivity of malignant peripheral nerve sheath tumors to MEK inhibition. Accepted for Poster Presentation at the CTOS Annual Meeting in New York, NY, 2013.
86. Ravi V, Ramesh N, Somaiah N, Leja MJ, Conley AP, Ludwig J, Araujo DM, Taylor S, Torres KE, Wang WL, Hunt KK, Reardon M, Benjamin R, Patel S. Cardiac angiosarcoma: clinical features and treatment outcomes. Accepted for Poster Presentation at the CTOS 2013 Annual Meeting in New York, NY, 2013.
87. Somaiah N, Ingram D, Liu J, Bolshakov S, Nguyen T, de Graaff M, Szuhai K, Aman P, Torres KE, Lev DC Nielsen TO, Bovee J, Lazar AJ. Establishment and characterization of a new human myxoid liposarcoma cell line (dl-221) with the fus-ddit3 translocation. Accepted for Poster Presentation at the CTOS 2013 Annual Meeting in New York, NY, 2013.
88. Demicco EG, Savannah K, Lusby K, Young ED, Ingram D, Bailey M, Montgomery K, Hornick J, van de Rijn M, Deavers M, Lev DC, Torres KE, Wang WL, Lazar AJ. Diagnostic utility of innumohistochemical markers in soft tissue and uterine leiomyosarcoma is limited in poorly differentiated tumors. Accepted for Poster Presentation at the CTOS 2013 Annual Meeting in New York, NY, 2013.
89. Bill K, Garnett J, Creighton C, Ma X, Meaux I, Nguyen T, Ingram D, Bolshakov S, Belousov R, Pollock R, Lev D, Torres KE, Lazar AJ. Integrated anaylsis of the molecular deregulations of the MDM2:p53. Accepted for Oral Presentation at the CTOS 2013 Annual Meeting in New York, NY, 2013.
90. Demicco E, Lusby K, Ingram D, Kivlin C, May C, Al Sannaa G, Vinod R, Lazar A, Cormier J, Hunt K, Feig B, Pollock R, Lev D, Torres KE. Immunohistochemical and Clinical Examination of Vascular Leiomyosarcoma Outcomes. Accepted for Poster Presentation at the CTOS 2013 Annual Meeting in New York, NY, 2013.
91. Al Sannaa G, Ingram D, Unlu O, Slopis J, McCutcheon I, Torres KE, Lazar A. The Impact of Neurofibromatosis Type 1 Status on Malignant Peripheral Nerve Sheath Tumors Patient Outcome. Accepted for Poster Presentation at the CTOS 2013 Annual Meeting in New York, NY, 2013.
92. Garnett J, Bill K, Shen L, Qiu P, Creighton C, Ingram D, Abbas G, Bolshakov S, Ma XY, Kivlin C, May C, Pollock R, Lev D, Torres KE, Lazar AJ. Identification of Signaling Changes and Potential Combination Therapies with MDM2 Inhibition in Dedifferentiated Liposarcoma Cells. Accepted for Poster Presentation at the CTOS 2013 Annual Meeting in New York, NY, 2013.
93. Torres KE, Kin K, Yi M, Lahat G, Arun B, Hunt KK, Pollock R, Lev D. Analysis of Radiation-Associated Angiosarcoma of the Breast. Accepted for oral presentation at the Society of Surgical Oncology's 65th Annual Cancer Symposium in Orlando, FL, 2012.
94. May C, Vu T, Liu J, Zhou F, Ma X, Ingram D, Belousov R, Han L, Lazar J, Lev D, Torres KE. Role of AXL as a Potential Therapeutic Target for Pleomorphic and Dedifferentiated Liposarcoma. Accepted for Poster Presentation at the Cancer Biology Chair and Director's Retreat in La Jolla, CA, 2012.
95. Torres KE, Vu T, Liu J, Lusby K, Kivlin C, Demicco E, Zhou F, Young E, Ingram D, Belousov R, Ma XY, Lazar A, Lev D. Role of AXL as Potential Therapeutic Target for Pleomorphic and Dedifferentiated Liposarcomas. Accepted for Poster Presentation at the CTOS 2012 Annual Meeting in Prague, Czech Republic, 2012.
96. Bill KL, Young E, Belousov R, Peng T, Nguyen T, Bolshakov S, Lazar A, Torres KE, Lev D. Met Signaling Contributes to Liposarcoma Growth, Migration, and Invasion: A Potential Molecular Therapeutic Target. Accepted for Poster presentation at the Connective Tissue Oncology Society Meeting in Chicago, IL, 2011.
97. Lopez G, Ghadimi M, Liu L, Belousov R, Torres KE, Lev D. Drug-Induced Authophagy as a Mechanism of Therapeutic Resistance in MPNST. Accepted for Poster presentation at the Connective Tissue Oncology Society Meeting in Chicago, IL, 2011.
98. Demicco E, Torres KE, Ghadimi M, Colombo C, Bolshakov S, Peng T, Hoffman A, Bovee J, Wang WL, Lev D, Lazar A. Involvement of the PI3K/AKT Pathway in Myxoid & Round Cell Liposarcoma. Accepted for Poster presentation at the Connective Tissue Oncology Society Meeting in Chicago, IL, 2011.
99. Lusby K, Torres KE, Kivlin C, Liu J, Vu T, Young E, Lazar A, Lev D. Expression of ―Drugable‖ Tryosine Kinase Receptors in MPNST: A Potential Role for AXL as a Novel Therapeutic Target. Accepted for Oral Presentation at the Connective Tissue Oncology Society Meeting in Chicago, IL, 2011.
100. Torres KE, Kin K, Lahat G, Arun B, Hunt KK, Pollock R, Lev D. Radiation-Associated Angiosarcoma of the Breast: A Single Institution Experience. Accepted for Poster presentation at the Connective Tissue Oncology Society Meeting in Chicago, IL, 2011.
101. Torres KE, Bill K, Lahat G, Liu J, Ghadimi M, Belousov R, Young E, Lopez G, Lazar A, Lev D. Met receptor: A potential therapeutic target for malignant peripheral nerve sheath tumors. Accepted for poster presentation at the Society of Surgical Oncology's 64th Annual Cancer Symposium in San Antonio, TX, 2011.
102. Lahat G, Tuvin D, Torres KE, Feig B, Cormier J, Hunt KK, Pisters P, Lev D, Pollock R. Extremity high grade soft tissue sarcoma (STS): outcomes in patients with primarily negative vs positive converted to negative microscopic margins following re-excision. Accepted for Oral presentation at the Connective Tissue Oncology Society Meeting in Paris, France, 2010.
103. Ghadimi MP, Liu P, Peng T, Torres KE, Young E, Wang W, Broccoli D, Lazar A, Pollock R, Lev D. A comprehensive clinicopathological study of pleomorphic liposarcomas. Accepted for Poster presentation at the Connective Tissue Oncology Society Meeting in Paris, France, 2010.
104. Lahat G, Zhu Q, Huang F, Bolshakov S, Liu J, Torres KE, Robert L, Lazar AL, Hung M, Lev D. Withaferin-a inhibits the growth, local recurrence, and metastasis of genetically complex STS. Accepted for Poster presentation at the Connective Tissue Oncology Society Meeting in Paris, France, 2010.
105. Torres KE, Lopez G, Liu J, Pollock RE, Lev DC. Role of drug-induced autophagy in malignant peripheral nerve sheath tumors (MPNST); a mechanism of drug resistance. Accepted for Poster presentation at the Annual Meeting of the American Association for Cancer Research in Washington, DC, 2010.
106. Lopez G, Liu J, Torres KE, Pollock RE, Lev DC. Histone deacetylase inhibitor (HDACi)-induced autophagy in malignant peripheral nerve sheath tumors (MPNST); a mechanism of drug resistance. Accepted for Abstract presentation at Keystone Symposia: Cell Death Pathways: Apoptosis, Autophagy and Necrosis in Vancouver, Canada, 2010.
107. Lopez G, Torres KE, Hernandez B, Liu J, Young E, Belousov R, Bolshakov S, Nguyen T, McConkey D, Lev D. Neurofibromatosis type-1 associated MPNST are highly sensitive to histone deacetylase inhibitors. Accepted for Oral presentation at the Connective Tissue Oncology Society Meeting in Paris, France, 2010.
108. Torres KE, Ghadimi M, Bill K, Liu J, Wang S, Lazar A, Pollock RE, Lev D. Role of c-MET as a prognostic factor and potential therapeutic target for malignant peripheral nerve sheath tumors. Accepted for Oral presentation at the Connective Tissue Oncology Society Meeting in Paris, France, 2010.
109. Torres KE, Katz D, Zou C, Zhu QS, Liu J, McCutcheon I, Slopis JM, Lazar AJ, Pollock RE, Lev D. Dual targeting of AKT and mTOR: a potential therapeutic approach for malignant peripheral nerve sheath tumor. Accepted for Oral presentation at the Connective Tissue Oncology Society Meeting in Miami, FL, 2009.
110. Wang S, Ren W, Liu J, Lahat G, Torres KE, Lopez G, Lazar AJ, Hayes-Jordan A, Liu J, Bankson KJ, Hazle JD, Lev D. TRAIL and doxorubicin combination induces pro-apoptotic and anti-angiogenic effects in soft tissue sarcoma in vivo. Accepted for Poster presentation at the Connective Tissue Oncology Society Meeting in Miami, FL, 2009.
111. Malik N, Keung EZ, Scally CP, Hunt KK, Torres KE, Lillemoe HA , Roland CL , Lyu HG. The Impact of Vascular Management on Complications in Patients with Retroperitoneal Leiomyosarcoma. 20th Annual Academic Surgical Congress in Las Vegas, NV.

Book Chapters

1. Torres KE and McCutcheon I. Neurogenic Tumors (Schwannoma, Neurofibroma, and MPNST) for Complex General Surgical Oncology. In: Official publication of the Society of Surgical Oncology (SSO). Decker Intellectual Properties Inc: Canada, 2018.
2. Keung EZ, Pollock RE, Hunt KK, Torres KE. Forequarter Amputation. In: Master Techniques in Surgery: Breast Surgery. Walters Kluwer, Lippincott Williams & Wilkins: Philadelphia, PA, 2018.
3. Torres KE, Pisters PW. Malignant fibrous histiocytoma. In: Sarcoma Oncology: A Multidisciplinary Approach. People's Medical Publishing House-USA, Ltd: China, 2014.
4. Brewer K, Torres KE, Lev D. Tumor Microenvironment Cross-Talk; a Process Critical for Sarcoma Progression and Metastasis. In: Sarcoma Oncology: A Multidisciplinary Approach. People's Medical Publishing House - USA, Ltd: China, 2014.
5. Torres KE, Pollock RE. Soft Tissue Sarcomas. In: New EBM Textbook of Elective General Surgery. People's Medical Publishing House - USA, Ltd: China, 2012.
6. Torres KE, Hunt KK, Pollock RE. Forequarter Amputation. In: Master Techniques in Breast Surgery. Lippincott Williams & Wilkins: New York, 2010.
7. Torres KE, Pollock RE. Gene-based therapies for cancer. In: Cancer Research. Springer: New York, 2010.
8. Torres, MB, Gingrich, AA and Torres KE. Surgical treatment of dermatofibrosarcoma protuberans and cutaneous leiomyosarcoma. In: Difficult Decisions in Surgery: An Evidence-Based Approach. In: Difficult Decisions in Surgical Oncology. Ed. Ben Ferguson, Michael G. White and Puneet Singh: Springer Nature: Chenna, India.